For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Acasti Pharma (ACST) is a stock that can certainly grab the ...
Today, Oppenheimer initiated coverage on ACST stock with an “outperform” rating and a price target of $6. Even after today’s significant price increase, the price target still represents upside of ...
Pharmaceutical company Acasti Pharma (NASDAQ:ACST) has a particular focus on developing drugs to help manage cardio-metabolic disorders. Traders might be interested in ACST stock if they like cheap ...
The average one-year price target for Acasti Pharma (NasdaqCM:ACST) has been revised to 6.12 / share. This is an increase of 200.00% from the prior estimate of 2.04 dated July 5, 2023. The price ...
Acasti Pharma (NASDAQ:ACST) just reported results for the first quarter of 2025. Acasti Pharma reported earnings per share of -24 cents. This was above the analyst estimate for EPS of -25 cents. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results